AALL1521; Ruxolitinib and Chemotherapy for Patients with JAK-Mutant B-ALL

AALL1521; Ruxolitinib and Chemotherapy for Patients with JAK-Mutant B-ALL

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description
This study is testing the safety and effectiveness of adding a targeted therapy (ruxolitinib) to standard chemotherapy for children, adolescents, and young adults with high-risk acute lymphoblastic leukemia with CRLF2 and other JAK pathway mutations.

Eligibility and criteria
IRB Number:
16-012888
Clinical trial phase:
Phase II
Official title:
AALL1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia (INCB 18424-269)

What to expect

Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.